IVL 745
Alternative Names: IVL-745Latest Information Update: 16 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Anti-inflammatories; Antiasthmatics; Propionic acids; Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 26 Jul 2002 Phase-II clinical trials in Asthma in Europe (unspecified route)
- 19 Jun 2000 Phase-I clinical trials for Asthma in Europe (Unknown route)